comprehensive -WSS

comprehensive

author：explore 2025-09-27 07:51:12 - browse：38174

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： As Maui death toll rises, number of missing remains unclear

leisure time

WSS

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Listen: Racing for gene therapy & a pioneering approval

Biohaven protein

Focused ultrasound for uterine fibroids: an uphill battle

ProMED sees offers of support, but its future remains unclear

AI used to predict Covid

entertainment

comprehensive

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The pain doctors face in trying to build their families

Drug repurposing or repositioning? The language matters

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

The high cost of giving birth even with insurance

Adam's Biotech Scorecard: Do Sarepta's exon

BioMarin wins approval for gene therapy to treat hemophilia A

Heat waves linked to early deliveries, preterm births in new study

Hollywood unions extend contract negotiations for actors

AI used to predict Covid

knowledge

Stigma and the return of syphilis

Insmed lung disease drug hits target in key Phase 3 trial

Insmed lung disease drug hits target in key Phase 3 trial

FDA approves first treatment for ultra

New definition of a human embryo proposed amid rapid advances

Health insurers say they are turning to AI to cut costs, improve care

hotspot

explore

leisure time

focus